Can-GARD/CCMG – The Leading Strand Series

Loading Events

This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers, clinicians and innovators.  The series will help attendees anticipate, access, and apply new approaches and technologies for patient care.


As of March 2024, the Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada.

Note, to obtain credit for this CPD activity, you must keep track of the seminars attended.  An easy way to do this is to download and save the certificate for each seminar attended which is available through the evaluation link sent after the seminar to attendees.  A letter at the end of the year will NOT be sent.



Title: Development of Gene Therapy for GM2 Gangliosidosis and Creatine Deficiency Disorders

It is all about developing gene therapies for genetic conditions.

Learning objectives:

  • Define ‘Gene Therapy’.
  • List at least three factors affecting gene therapy outcomes.
  • List at least three conditions that can be treated by gene therapy- approved products.
  • List at least three ethical issues with gene therapy.


Speaker: Dr. Jagdeep Walia


Dr. Jagdeep Walia is a medical geneticist and full-time professor in the Division of Medical Genetics, Department of Pediatrics. A medical school graduate from India, he finished his residency in Medical Genetics from University of Manitoba and then joined Queen’s University in 2012 as a clinical Geneticist.

Dr. Walia’s research lab focuses on developing novel gene therapy approaches for inherited and acquired neurodegenerative disorders. His focus is on GM2 gangliosidoses, creatine deficiency disorders, galactosemia and 2 rare autism spectrum disorders. The translational nature of this work is exemplified by the initiation of a phase 1/2 clinical trial for infantile GM2 gangliosidoses at Queen’s University/Kingston Health Sciences Centre using adeno-associated virus vector (AAV) as a tool for gene transfer to the central and peripheral nervous system. He has published more than 50 peer-reviewed articles and has been invited as a speaker on the topic of gene therapy for local, national and international conferences.

Friday, September 29, 2023
Friday, October 27, 2023
Friday, November 24, 2023
Friday, December 15, 2023 @ 12:30pm – 1:30pm ET
Friday, January 26, 2024
Friday, February 23, 2024
Friday, March 22, 2024
Friday, April 26, 2024
Friday, May 31, 2024
Friday, June 28, 2024

Go to Top